In August, Turnstone Biologics Corp. saw a 127% increase in short interest to 476,400 shares.
In August, Turnstone Biologics Corp. (NASDAQ: TSBX) experienced a 127% rise in short interest, totaling 476,400 shares, or 3.5% of its stock. The stock opened at $0.66, following an earnings miss of $0.08 per share. Bank of America lowered its price target from $12.00 to $10.00, while Piper Sandler reduced its target from $20.00 to $3.75. Turnstone specializes in developing treatments for solid tumors.
September 14, 2024
3 Articles